Just like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has shown that PV is associated with a lower quality of life in measures ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

CATHERINE M. BROOME: Polycythemia vera is a blood disorder that is associated with an increase in production of the red blood cells. But white blood cells and platelets may also be affected.

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Patients with polycythemia vera often have enlarged spleen and additional debilitating symptoms. Many patients treated with commonly available therapies become intolerant or resistant, which then ...

Q1 2025 Management View CEO Herve Hoppenot highlighted strong financial performance in Q1 2025, with total revenues reaching ...

Right now, as I mentioned, our standard therapy for patients with polycythemia vera is to bring them in regularly and drain them of their blood. That is pretty archaic and sounds like something we ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera ...

Panelists discuss how thrombotic risk assessment—anchored in age, thrombotic history, and additional factors like leukocytosis and JAK2 allele burden—guides personalized therapy in polycythemia vera ...

Based on their trove of data, these investigators believe that classification of Philadelphia chromosome-negative MPN may be too simple. MedPage Today spoke with Jerry Spivak, MD, Director of the ...

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients ...